StonvexLoading…
StonvexStonvexStonvexCore line items from FEMY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.29M | $1.63M | $1.07M | $1.21M |
Operating Income | $-17.59M | $-17.79M | $-14.51M | $-11.60M |
Net Income | $-18.63M | $-18.82M | $-14.25M | $-11.39M |
EPS (Diluted) | $-0.47 | $-0.85 | $-0.93 | $-0.96 |
Total Assets | $20.72M | $12.45M | $27.76M | $16.90M |
Total Liabilities | $14.85M | $10.14M | $9.40M | $1.65M |
Cash & Equivalents | $9.27M | $3.45M | $21.72M | $12.96M |
Free Cash Flow OCF − CapEx | $-19.22M | $-20.21M | $-11.42M | $-11.14M |
Shares Outstanding | 59.60M | 23.36M | 21.66M | 11.87M |